Anuh Pharma Limited has informed the Exchange regarding 'Appointment Of Scrutinizer For The 66Th Annual General Meeting.'.

Revenue Growth 20pctPat NegativeEbitda Margin CompressionAuditor Mid Year ChangeNegative Operating CashflowResults View source PDF

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-6.2%1-day move

₹81.50

prior close

₹80.81

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-3.5-3.5-4.3-4.6-6.2-6.3-6.1-6.1-6.1-7.5-2.5-3.2-1.4—

Up moveDown movePending

AI summary

Anuh Pharma Limited reported FY26 results with revenue from operations of Rs. 77,166 Lakhs, up 16.6% from Rs. 66,151 Lakhs in FY25. However, profit after tax declined 13.3% to Rs. 4,105 Lakhs from Rs. 4,735 Lakhs. EBITDA margin compressed significantly from 10.64% to 8.56%, a drop of 208 basis points. The board recommended a dividend of Rs. 1.50 per share (30% payout). Operating cash flow turned negative at Rs. 301 Lakhs compared to positive Rs. 3,712 Lakhs in FY25, indicating working capital pressure with inventories nearly doubling to Rs. 14,776 Lakhs. Nine promoter group shareholders holding 0.95% stake requested reclassification to public category. The company also appointed new internal auditors and a quality head.

Likely market impact

Despite revenue growth, the stock may face pressure due to declining profitability, margin compression, and negative operating cash flow. The dividend recommendation provides some support for shareholders.